表紙
市場調查報告書

再生不良性貧血:開發中產品分析

Aplastic Anemia - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 245971
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
再生不良性貧血:開發中產品分析 Aplastic Anemia - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 110 Pages
簡介

再生不良性貧血是具有末梢性全血球減少症及骨髓形成不全等特徵的骨髓損傷症。症狀有疲勞,膚色青白,心律急速或不規則,運動性喘不過氣,鼻血,齒齦出血,長刀傷造成的出血,皮疹,暈眩,頭痛等。危險因素有暴露在有毒的化學物質,癌症的高輻射劑量放射治療或化療,特定的血液疾病,自體免疫不全,嚴重的感染疾病等。治療有使用免疫抑製藥與幹細胞移植等。

本報告提供全球各國治療再生不良性貧血所用的開發中產品開發情形相關分析,提供開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查結果。

簡介

  • 分析範圍

再生不良性貧血概要

治療藥的開發

  • 再生不良性貧血開發中產品:概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

再生不良性貧血開發治療藥的企業

  • 3SBio Inc
  • Acceleron Pharma Inc
  • Amgen Inc
  • BioLineRx Ltd
  • F. Hoffmann-La Roche Ltd
  • Gamida Cell Ltd
  • Novartis AG
  • Pluristem Therapeutics Inc
  • Regen BioPharma Inc

藥物簡介

暫停的計劃

開發中止的產品

再生不良性貧血相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12203IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Pipeline Review, H1 2020, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Aplastic Anemia - Overview
  • Aplastic Anemia - Therapeutics Development
  • Aplastic Anemia - Therapeutics Assessment
  • Aplastic Anemia - Companies Involved in Therapeutics Development
  • Aplastic Anemia - Drug Profiles
  • Aplastic Anemia - Dormant Projects
  • Aplastic Anemia - Discontinued Products
  • Aplastic Anemia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Aplastic Anemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Aplastic Anemia - Pipeline by Acceleron Pharma Inc, H1 2020
  • Aplastic Anemia - Pipeline by Amgen Inc, H1 2020
  • Aplastic Anemia - Pipeline by ASC Therapeutics Inc, H1 2020
  • Aplastic Anemia - Pipeline by BioLineRx Ltd, H1 2020
  • Aplastic Anemia - Pipeline by Cell Source Inc, H1 2020
  • Aplastic Anemia - Pipeline by Cellenkos Inc, H1 2020
  • Aplastic Anemia - Pipeline by Elixirgen Therapeutics LLC, H1 2020
  • Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Aplastic Anemia - Pipeline by Gamida Cell Ltd, H1 2020
  • Aplastic Anemia - Pipeline by HemoGenyx LLC, H1 2020
  • Aplastic Anemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
  • Aplastic Anemia - Pipeline by Novartis AG, H1 2020
  • Aplastic Anemia - Pipeline by Pfizer Inc, H1 2020
  • Aplastic Anemia - Pipeline by Regen BioPharma Inc, H1 2020
  • Aplastic Anemia - Dormant Projects, H1 2020
  • Aplastic Anemia - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Aplastic Anemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020